Expanding market share in global markets and enhancing brand value
First written in FY2016. 28 of 39 entries say "Advanced", first in FY2017-Q3. Latest entry: 2026-08-07.
0 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedEarnings
「Overseas revenue increased 24.1% year on year as the Interventional Systems business, centered on access products, and the main businesses of the Blood and Cell Technologies Company expanded, with foreign exchange also contributing.」
Overseas revenue increased 24.1% year on year, indicating continued business expansion in global markets. - FY2026AdvancedAnnual report
「Overseas revenue increased 11.0% year on year as Global Blood Solutions expanded, driven by the accelerated development of the Interventional Systems business, centered on access products, and the plasma innovation business.」
Overseas revenue rose 11.0% from the previous fiscal year to ¥909.3 billion. The development of the Interventional Systems business and the Plasma Innovation business drove growth in global markets. - 2026-05-15AdvancedEarnings
「Overseas revenue increased 11.0% year on year as Global Blood Solutions expanded, driven by the accelerated development of the Interventional Systems business, centered on access products, and the plasma innovation business.」
Overseas revenue increased 11.0% year on year, with expansion of the Interventional Systems business and the plasma innovation business identified as growth drivers. - FY2026-H1AdvancedAnnual report
「Overseas revenue increased 5.8% year on year, against a backdrop of expansion in the Interventional Systems business, centered on access products, and the Plasma Innovation business.」
Overseas revenue increased 5.8% year on year, or 9.4% excluding the impact of foreign exchange. Expansion of the Interventional Systems business and the Plasma Innovation business drove growth in global markets. - FY2025AdvancedAnnual report
「Overseas, Global Blood Solutions expanded as the Interventional Systems business, centered on access products, and the Plasma Innovation business accelerated their expansion, while foreign exchange also contributed, resulting in a 15.2% increase in revenue from the previous fiscal year.」
Overseas revenue rose 15.2% from the previous fiscal year to ¥819.0 billion. Expansion of the Interventional Systems business and the Plasma Innovation business drove growth in global markets. - FY2025-H1AdvancedAnnual report
「Overseas, demand for the TIS (catheter) business and the business serving blood centers expanded, and foreign exchange also contributed, resulting in a 17.2% increase in revenue year on year.」
Overseas revenue increased 17.2% year on year, with expanded demand for the TIS business and the business serving blood centers driving growth in global markets. - FY2024AdvancedAnnual report
「Overseas, demand for the TIS (catheter) business and the business serving blood centers expanded, and foreign exchange also contributed, resulting in a 16.0% increase in revenue from the previous fiscal year.」
Overseas revenue rose 16.0% from the previous fiscal year to ¥710.7 billion, indicating progress in business expansion in global markets over the full year. - FY2024-Q3AdvancedAnnual report
「Overseas, demand for the TIS (catheter) business and the business serving blood centers expanded, and foreign exchange also contributed, resulting in a 13.7% increase in revenue year on year.」
Overseas revenue increased 13.7% year on year, or 7.8% excluding the impact of foreign exchange. Expanded demand for the TIS business and the business serving blood centers drove growth in global markets. - FY2024-Q2AdvancedAnnual report
「Overseas, demand for the TIS (catheter) business and the business serving blood centers expanded, and foreign exchange also contributed, resulting in a 13.5% increase in revenue year on year.」
Overseas revenue increased 13.5% year on year, or 7.8% excluding the impact of foreign exchange. Expanded demand for the TIS business and the business serving blood centers drove overseas growth. - FY2024-Q1AdvancedAnnual report
「Overseas, demand for the TIS (catheter) business and the business serving blood centers expanded, and foreign exchange also contributed, resulting in a 13.8% increase in revenue year on year.」
Overseas revenue increased 13.8% year on year, or 8.3% excluding the impact of foreign exchange. Expanded demand for the TIS business and the business serving blood centers drove overseas growth. - FY2023AdvancedAnnual report
「Overseas, all businesses performed strongly as medical demand recovered and grew, with new products contributing particularly to the Vascular business, resulting in a 23.3% increase in revenue year on year.」
Overseas revenue rose 23.3% from the previous fiscal year to ¥612.8 billion. All companies and businesses grew, led by the Vascular business, and growth in global markets progressed over the full year. - FY2023-Q3AdvancedAnnual report
「Overseas, as medical demand recovered, all companies grew by double digits, led by the TIS (catheter) business, resulting in a 25.1% increase in revenue year on year.」
Overseas revenue increased 25.1% year on year, or 7.5% excluding the impact of foreign exchange. All 3 companies achieved double-digit growth, led by the TIS business, demonstrating progress in expanding its presence in global markets. - FY2023-Q2AdvancedAnnual report
「Overseas, as medical demand recovered, all 3 companies grew by double digits or more, resulting in a 24.7% increase in revenue year on year. Even excluding the impact of foreign exchange, all regions grew, led by the 14.3% increase in Asia and other regions, while overseas revenue overall increased 7.8%.」
Overseas revenue increased 24.7% year on year, or 7.8% excluding the impact of foreign exchange, with all 3 companies achieving double-digit or higher growth. - FY2023-Q1AdvancedAnnual report
「Overseas, demand recovered significantly in the Cardiovascular Company's TIS and Neurovascular businesses and in the Blood and Cell Technologies Company, resulting in a 20.3% increase in revenue year on year.」
Overseas revenue increased 20.3% year on year, with the recovery in demand in TIS, Neurovascular, and Blood and Cell Technologies driving growth in global markets. - FY2022AdvancedAnnual report
「Revenue for the period performed strongly as demand in the cardiovascular field, which had declined due to the impact of COVID-19, recovered overseas, particularly in Europe and the United States. In Japan, although demand in the cardiovascular field recovered slowly, the Company captured new medical demand, including through the supply of syringes for COVID-19 vaccines, and revenue remained firm. As a result, helped by the positive impact of the weaker yen on foreign exchange, revenue rose 14.6% from the previous fiscal year to ¥703.3 billion.」
Overseas revenue rose 20.6% from the previous fiscal year to ¥497.2 billion, reflecting progress in growth in global markets driven by the recovery in demand, particularly in Europe and the United States, and the capture of new medical demand. - FY2022-Q3AdvancedAnnual report
「Overseas, demand recovered significantly in the Cardiovascular Company's TIS and Neurovascular businesses and in the Blood and Cell Technologies Company, resulting in a 22.7% increase in revenue year on year.」
Overseas revenue increased 22.7% year on year, or 15.5% excluding the impact of foreign exchange. The recovery in demand in the Cardiovascular and Blood and Cell Technologies fields drove growth in global markets. - FY2022-Q2AdvancedAnnual report
「Overseas, demand recovered significantly in the Cardiovascular Company's TIS and Neurovascular businesses and in the Blood and Cell Technologies Company, resulting in a 27.6% increase in revenue year on year.」
Overseas revenue increased 27.6% year on year, with the recovery in demand in the Cardiovascular and Blood and Cell Technologies fields driving growth in global markets. - FY2022-Q1AdvancedAnnual report
「Overseas, demand recovered significantly in the Cardiovascular Company's TIS and Neurovascular businesses and in the Blood and Cell Technologies Company, resulting in a 40.9% increase in revenue year on year.」
Overseas revenue increased 40.9% year on year. The recovery in demand for TIS, Neurovascular, and Blood and Cell Technologies drove growth in overseas markets. - FY2021Continued overseas revenue declineAnnual report
「Overseas, although the spread of COVID-19 had a limited impact on the Hospital Company and Blood and Cell Technologies Company, it had a significant impact on the Cardiovascular Company, particularly the TIS (catheter) business, resulting in a 4.7% decline in revenue from the previous fiscal year.」
Overseas revenue was ¥412.1 billion, down 4.7% from the previous fiscal year, indicating that growth in overseas markets also declined for the full year. - FY2021-Q3Continued decline in overseas revenueAnnual report
「Overseas, although the spread of COVID-19 had a limited impact on the Hospital Company and Blood and Cell Technologies Company, it had a significant impact on the Cardiovascular Company, particularly the TIS (catheter) business, resulting in a 6.8% decline in revenue year on year.」
Overseas revenue declined 6.8% year on year, with the Cardiovascular Company, particularly the TIS (catheter) business, the main cause of the decline in overseas revenue. - FY2021-Q2Partial recovery in overseas demandAnnual report
「Overseas, although the spread of COVID-19 had a limited impact on the Hospital Company and Blood and Cell Technologies Company, it had a significant impact on the Cardiovascular Company, particularly the TIS (catheter) business, resulting in a 10.2% decline in revenue year on year. Meanwhile, in the cardiovascular field, demand recovered significantly as some procedures postponed in the first quarter were performed in the second quarter.」
Overseas revenue continued to decline, down 10.2% year on year, but some procedures postponed in the first quarter were performed in the second quarter, resulting in a significant recovery in demand in the cardiovascular field. - FY2021-Q1Decline in overseas growthAnnual report
「Overseas, although the spread of COVID-19 had a limited impact on the Hospital Company and Blood and Cell Technologies Company, it had a significant impact on the Cardiovascular Company, particularly the TIS (catheter) business, resulting in an 18.4% decline in revenue.」
Overseas revenue declined 18.4% year on year, and progress toward expanding market share and presence in global markets temporarily regressed due to the impact of the spread of COVID-19. - FY2020AdvancedAnnual report
「Overseas, although China was affected by the spread of COVID-19 in the fourth quarter, the TIS business expanded steadily and the Neurovascular business performed strongly, resulting in higher revenue.」
Overseas revenue was ¥432.5 billion, up 5.2% from the previous fiscal year. Although China was affected by the spread of COVID-19, the TIS and Neurovascular businesses led the increase in overseas revenue. - FY2020-Q3AdvancedAnnual report
「Overseas total 301,364 322,302 6.9 11.7」
Overseas revenue increased 6.9% year on year, or 11.7% excluding the impact of foreign exchange. This indicates higher sales in global markets, led by the Americas and Asia and other regions. - FY2020-Q2AdvancedAnnual report
「Overseas total 193,921 211,356 9.0 13.4」
Overseas revenue increased 9.0% year on year, or 13.4% excluding the impact of foreign exchange. This indicates higher sales in global markets, led by the Americas and Asia and other regions. - FY2020-Q1AdvancedAnnual report
「Overseas total 106,572 7.6 10.4」
Overseas revenue increased 7.6% year on year, or 10.4% excluding the impact of foreign exchange. This indicates higher sales in overseas markets, led by the Americas and Asia and other regions. - FY2019AdvancedAnnual report
「Overseas 411,013 12,093 3.0」
Overseas revenue was ¥411.0 billion, up 3.0% from the previous fiscal year. Full-year results demonstrate growth in the overseas business related to expanding its presence in global markets. - FY2019-Q3AdvancedAnnual report
「Overseas total 301,364 2.5 3.7」
Overseas revenue increased 2.5% year on year, or 3.7% excluding the impact of foreign exchange. The figures demonstrate progress in the overseas business related to expanding its presence in global markets. - FY2019-Q2AdvancedAnnual report
「Overseas total 193,921 0.9 1.3」
Overseas revenue increased 0.9% year on year, or 1.3% excluding the impact of foreign exchange. Neurovascular, Alliance and products for blood centers led overseas revenue growth. - FY2019-Q1AdvancedAnnual report
「Overseas total 94,397 99,009 4.9 4.1」
Overseas revenue increased 4.9% year on year, or 4.1% excluding the impact of foreign exchange. Neurovascular, CV, Alliance, products for blood centers and apheresis therapy products led overseas growth. - FY2018AdvancedAnnual report
「As a result, overseas revenue increased by double digits overall, and revenue at the Cardiovascular Company rose 23.9% year on year to ¥324.0 billion.」
Overseas revenue in the Cardiovascular business, which is related to improving its global presence and brand, increased by double digits overall, rising 23.9% year on year. - FY2018-Q3RestatedAnnual report
「Against this backdrop, the Group is pursuing management based on a medium- to long-term vision of becoming a manufacturer trusted worldwide as a leading brand in healthcare, while earning world-class trust in total quality, including products, supply and services, as a “global company originating in Japan.”」
It continues to indicate its goal of becoming a manufacturer trusted by healthcare professionals worldwide as a leading brand. - FY2018-Q2RestatedAnnual report
「Against this backdrop, the Group is pursuing management based on a medium- to long-term vision of becoming a manufacturer trusted worldwide as a leading brand in healthcare, while earning world-class trust in total quality, including products, supply and services, as a “global company originating in Japan.”」
It continues to indicate its goal of becoming a manufacturer trusted by healthcare professionals worldwide as a leading brand. - FY2018-Q1ReframedAnnual report
「Against this backdrop, the Group is pursuing management based on a medium- to long-term vision of becoming a manufacturer trusted worldwide as a leading brand in healthcare, while earning world-class trust in total quality, including products, supply and services, as a “global company originating in Japan.”」
The direction of aiming to strengthen its global presence and become a leading brand in each area in which it operates has been restructured as the goal of becoming a manufacturer trusted by healthcare professionals worldwide as a leading brand. - FY2017RaisedAnnual report
「The Cardiovascular Company has set as its vision for medium- to long-term growth to be recognized as a leading brand in the cardiovascular field by healthcare professionals worldwide. To achieve this, we will rank among the top 3 in each area in which we operate, enhance total quality, including our products, supply and services, and provide value that is needed by healthcare professionals worldwide.」
It set out a more specific and ambitious target for improving its global presence and brand value, aiming to rank among the top 3 in each area in which it operates. - FY2017-Q3AdvancedAnnual report
「This is expected to significantly strengthen our presence in the United States, the world's largest medical device market.」
The acquisition of St. Jude Medical's business by Abbott represented concrete progress toward significantly strengthening the Company's global presence in the U.S. market. - FY2017-Q2RestatedAnnual report
「As one of the policies of its new growth strategy, the Company aims to expand its global presence in business fields with expected growth and competitiveness.」
The Company reiterates the expansion of its global presence as a policy of its new growth strategy. - FY2017-Q1RestatedAnnual report
「As one of the policies of its new growth strategy, the Company aims to expand its global presence in business fields with expected growth and competitiveness.」
The Company reiterates the expansion of its global presence as a policy of its new growth strategy. - FY2016First statedAnnual report
「The Company will work to maximize corporate value by strengthening its position as a domestic leader in the healthcare industry and expanding its share and enhancing its brand value in global markets.」
The Company identifies strengthening its domestic leadership base and improving its share and brand in global markets as means of maximizing corporate value.